Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Biomarker for predicting responsiveness of lung adenocarcinoma to platinum-containing double-drug chemotherapy, and related product of biomarker

A marker, lung adenocarcinoma technology, applied in the field of biomedicine, can solve problems such as difficult to predict and sensitivity

Inactive Publication Date: 2021-12-24
QINGDAO MEDINTELL BIOMEDICAL CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, conventional methods for the treatment of lung adenocarcinoma include surgery, platinum-containing double-drug chemotherapy, radiotherapy, and targeted therapy. Platinum-containing double-drug chemotherapy refers to the combination of platinum chemotherapy drugs (carboplatin, cisplatin) and other non-platinum single drugs (paclitaxel, gemcitabine, vinorelbine). ) combined application, but it is still difficult to predict which lung adenocarcinoma patients will be sensitive to platinum-containing double-drug chemotherapy regimens, and predicting the sensitivity or response of lung adenocarcinoma patients to platinum-containing double-drug chemotherapy is still a huge challenge Therefore, it is of great significance in this field to discover biomarkers that can be used to accurately predict the sensitivity of lung adenocarcinoma to platinum-containing double-drug chemotherapy, and to apply it to the screening of patients with lung adenocarcinoma before chemotherapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarker for predicting responsiveness of lung adenocarcinoma to platinum-containing double-drug chemotherapy, and related product of biomarker
  • Biomarker for predicting responsiveness of lung adenocarcinoma to platinum-containing double-drug chemotherapy, and related product of biomarker
  • Biomarker for predicting responsiveness of lung adenocarcinoma to platinum-containing double-drug chemotherapy, and related product of biomarker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0075] Example 1 Gene screening related to sensitivity of lung adenocarcinoma to platinum-containing double-drug chemotherapy

[0076] 1. Data source

[0077] Before pathologically diagnosed lung adenocarcinoma patients received platinum-containing double-drug chemotherapy, their tumor tissues were collected, and according to whether lung adenocarcinoma responded to platinum-containing double-drug chemotherapy, combined with RECIST (Response Evaluation Criteria for Solid Tumors) guidelines, the above-mentioned Patients with lung adenocarcinoma were divided into response group (R, responder) or non-response group (NR, non-responder); the patients with lung adenocarcinoma had not received platinum-based chemotherapy before receiving platinum-containing double-drug chemotherapy; all The responding group includes lung adenocarcinoma patients with complete response (CR, complete response) and lung adenocarcinoma patients with partial response (PR, partial response), and the non-res...

Embodiment 2

[0082] Application of differentially expressed genes screened in Example 2 in predicting sensitivity of lung adenocarcinoma to platinum-containing double-drug chemotherapy

[0083] 1. Experimental method

[0084] For the genes differentially expressed between the responder group and the non-response group screened in Example 1, receiver operating characteristic (ROC) analysis was performed using the R package "pROC" (version 1.15.0), and the receiver operating characteristic (ROC) was calculated. The area under the characteristic curve (AUC) was used to evaluate the accuracy of a single differentially expressed gene, a combination of any two differentially expressed genes, and a combination of three differentially expressed genes in predicting the sensitivity of lung adenocarcinoma to platinum-containing double-drug chemotherapy, wherein the The range of AUC value is 0-1;

[0085] Among them, when judging the diagnostic efficiency of a single differentially expressed gene in ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a biomarker for predicting the responsiveness of lung adenocarcinoma to platinum-containing double-drug chemotherapy and a related product of the biomarker. The miRNA comprises miR-31, miR-449a and / or miR-483-5p, and verification shows that the miRNA serving as the marker for predicting the sensitivity of the lung adenocarcinoma to the platinum-containing double-drug chemotherapy has relatively high diagnosis efficiency and has a good application prospect in clinically assisting doctors to judge the sensitivity or the reactivity of a subject to the platinum-containing double-drug chemotherapy.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, in particular, the invention relates to biomarkers and related products for predicting the responsiveness of lung adenocarcinoma to platinum-containing double-drug chemotherapy. Background technique [0002] Lung cancer (Lung cancer) is the malignant tumor with the highest morbidity and mortality worldwide, among which non-small cell lung cancer (Non-small cell lung cancer, NSCLC) accounts for 80%, and lung adenocarcinoma (Lung adenocarcinoma) is the most common form of NSCLC. Main histological types (Ji P, Diederichs S, Wang W, et al. MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancer [J]. Oncogene, 2003, 22 (39 ):8031-8041.). Although the current research and clinical trials on lung cancer are progressing rapidly, the prognosis of lung cancer is still poor, 80-85% of patients are diagnosed at advanced stage, and the 5-y...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886A61K45/00A61P35/00G16B5/00G16H70/60G16H70/40
CPCC12Q1/6886A61K45/00A61P35/00G16B5/00G16H70/60G16H70/40C12Q2600/158C12Q2600/178C12Q2600/106
Inventor 杨承刚郭静李雨晨范冰燕
Owner QINGDAO MEDINTELL BIOMEDICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com